Gene · 3903
Papers1,353
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,353
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrative Omics Analysis Reveals a CD206+ Macrophage/Dendritic Cell-CD155-TIGIT+ Regulatory T Cell Axis as a Protective Immune Checkpoint Pathway in Atherosclerosis Progression. | Barrier Immun | 2026 | 42819567 | PubTator, text mining | PubMed |
| Type I collagen matrix signaling in cancer: receptor sensing and mechanotransduction. | Cell Signal | 2026 | 42660397 | PubTator, text mining | PubMed |
| A dual pronged approach to cancer immune exclusion: tumor-derived LAIR-1 simultaneously drives fibrosis and blocks immune recruitment in glioma. | Res Sq | 2026 | 42620371 | PubTator, text mining | PubMed |
| Machine learning-driven development of a novel unfolded protein response-related gene signature for predicting lung adenocarcinoma patient prognosis. | BMC Cancer | 2026 | 42401850 | PubTator, text mining | PubMed |
Decoding chromatin regulator-LAIR1+ M2 like macrophage patterns in atherosclerosis and clinical outcomes of Lung adenocarcinoma patients: evidence from artificial intelligence-driven multi omics and in vitro validation. | Clin Exp Med | 2026 | 42319401 | PubTator, text mining | PubMed |
| Unveiling LAIR1: a prognostic biomarker associated with gastric cancer progression and metastasis. | Transl Cancer Res | 2026 | 42305472 | PubTator, text mining | PubMed |
| Development and validation of an m6A and autophagy related lncRNAs signature for predicting survival and modulating the immune microenvironment in esophageal squamous cell carcinoma. | Front Immunol | 2026 | 42292425 | PubTator, text mining | PubMed |
| Serum proteomic atlas reveals distinct molecular signatures of lupus nephritis activity, chronicity, and treatment response. | bioRxiv | 2026 | 42182176 | PubTator, text mining | PubMed |
| Multimodal transcriptomics reveal myCAF-derived collagen signaling associated with impaired NK-cell cytotoxicity and immune exclusion in pancreatic cancer. | J Transl Med | 2026 | 42174623 | PubTator, text mining | PubMed |
| A multimodal atlas for immunotherapeutic targeting of AML surface heterogeneity. | iScience | 2026 | 41959675 | PubTator, text mining | PubMed |
| Current Insights into Clinical, Molecular, and Therapeutic Approaches to Acute Respiratory Distress Syndrome. | Med Sci (Basel) | 2026 | 41892849 | PubTator, text mining | PubMed |
| Clinical Evolution of a Cohort of Patients with COVID-19 Treated with Usual Medical Care Plus Polymerized Type I Collagen During the Pandemic Emergency. | Med Sci (Basel) | 2026 | 41892833 | PubTator, text mining | PubMed |
| Inflammatory protein profiling in immune cells identifies molecular signatures for enhanced diagnostic precision in psoriatic arthritis. | Mol Biomed | 2026 | 41851388 | PubTator, text mining | PubMed |
| Differences in the expression profiles of m6A-related genes and the prognostic role in immunotherapy for lung adenocarcinoma patients. | Front Oncol | 2026 | 41809822 | PubTator, text mining | PubMed |
| The extracellular matrix in inflammation and cancer. | Mol Biomed | 2026 | 41787034 | PubTator, text mining | PubMed |
| Altered transposon element-derived genes distort oxygen-free radical scavenger systems in FXD. | NAR Mol Med | 2026 | 41768973 | PubTator, text mining | PubMed |
| Immunosuppressive Environment of Pancreatic NENs-A Review. | Biomedicines | 2026 | 41751264 | PubTator, text mining | PubMed |
| A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma. | Oncoimmunology | 2026 | 41732954 | PubTator, text mining | PubMed |
| Prognostic model based on stem cells and oxidative stress related genes for ovarian cancer. | Medicine (Baltimore) | 2026 | 41731838 | PubTator, text mining | PubMed |
| T Cell Exhaustion in Hepatocellular Carcinoma: A Substantial Barrier in Immunotherapy. | J Cell Mol Med | 2026 | 41645702 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3903/papers